Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutathione in Children With Autism Spectrum Disorder
NCT05954052Phase 4Terminated
- Sponsor
- University of Chicago
- Start
- Jul 2019
- Primary completion
- Aug 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glutathione in Autism Spectrum Disorder (ASD), sponsored by University of Chicago. Primary endpoint: Aberrant Child Checklist (ABC) at 12 weeks. Started Jul 2019; status: terminated.
02
Drugs
glutathione
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05954052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954052.